Can platelet function tests predict the clinical efficacy of aspirin?

Seminars in Thrombosis and Hemostasis

Volumn 31, Issue 4, 2005, Pages 404-410

  Haubelt, Hannelore ^a   Anders, Christof ^a   Hellstern, Peter ^a  

^a Academic City Hospital   (Germany)

Author keywords

Aspirin; Aspirin nonresponsiveness; Platelet function tests; Predictive value

Indexed keywords

ACETYLSALICYLIC ACID;

ANALYZER; BLOOD CLOTTING PARAMETERS; CARDIOVASCULAR SYSTEM; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG MONITORING; FLOW CYTOMETRY; HUMAN; LABORATORY TEST; PRIORITY JOURNAL; RELIABILITY; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA;

ADENOSINE DIPHOSPHATE; ASPIRIN; BLOOD PLATELETS; CLINICAL TRIALS; DRUG RESISTANCE; FLOW CYTOMETRY; HUMANS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; THROMBOXANE B2; TIME FACTORS;

EID: 25444506642     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2005-916674     Document Type: Conference Paper

References (42)

1. Schrör K. Aspirin and platelets: the antiplatelet action of aspirin and its role in thrombosis treatment and prophylaxis. Semin Thromb Hemost 1997;23:349-356
2. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129-135
3. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86
4. Patrono C, Coller B, Dalen JE, et al. Platelet active drugs. The relationships among dose, effectiveness, and side effects. Chest 2001;119:39S-63S
5. Cambria-Kiely JA, Gandhi PJ. Aspirin resistance and genetic polymorphisms. J Thromb Thrombolysis 2002;14:51-58
6. McKee SA, Sane DC, Deliagyris N. Aspirin resistance in cardiovascular disease: a review of prevalence, mechanisms, and clinical significance. Thromb Haemost 2002;88:711-715
7. Howard PA. Aspirin resistance. Ann Pharmacother 2002;36:1620-1624
8. Halushka MK, Walker LP, Halushka PV. Genetic variation in cyclooxygenase-1: effects on response to aspirin. Clin Pharmacol Ther 2003;73:122-130
9. Grotemeyer KH, Scharafinski HW, Husstedt IW. Two-year follow-up of aspirin responder and aspirin non responder. A pilot study including 180 post-stroke patients. Thromb Res 1993;71:397-403
10. Mueller MR, Salat A, Stangl P, et al. Variable platelet response to low-dose ASA and the link of limb deterioration in patients submitted to peripheral arterial angioplasty. Thromb Haemost 1997;78:1003-1007
11. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965
12. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-929
13. Born GV, Dearnley R, Foulks JG, Sharp DE. Quantification of the morphological reaction of platelets to aggregating agents and of its reversal by aggregation inhibitors. J Physiol 1978;280:193-212
14. Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behaviour in blood. J Pharmacol Methods 1980;3:135-158
15. Wu KK, Hoak JC. A new method for quantitative detection of platelet aggregates in patients with arterial insufficiency. Lancet 1974;22:924-926
16. Grotemeyer KH. The platelet reactivity test. A useful by-product of the blood sampling procedure? Thromb Res 1991;61:423-431
17. Hurlen M, Seljeflot I, Arnesen H. The effect of different antithrombotic regimens on platelet aggregation after myocardial infarction. Scand Cardiovasc J 1998;32:233-237
18. Kratzer MA, Born GV. Simulation of primary haemostasis in vitro. Haemostasis 1985;15:357-362
19. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 2001;88:230-235
20. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655
21. Weber AA, Przytulski B, Schanz A, Hohlfeld T, Schör K. Towards a definition of aspirin resistance: a typological approach. Platelets 2002;13:37-40
22. Breddin K, Ziemen M, Bauer O, et al. Time and temperature dependent changes of ADP- and collagen-induced and "spontaneous" aggregation. Thromb Res 1980;19:621-638
23. Nicholson NS, Panzer-Knodle SG, Haas NF, et al. Assessment of platelet function assays. Am Heart J 1998;135:S170-S178
24. Sane DC, McKee SA, Malinin AI, Serebruany VL. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am J Cardiol 2002;90:893-895
25. Helgason CM, Tortorice KL, Winkler SR, et al. Aspirin response and failure in cerebral infarction. Stroke 1993;24:345-350
26. Helgason CM, Bolin KM, Hoff JA, et al. Development of aspirin resistance in persons with previous ischemic stroke. Stroke 1994;25:2331-2336
27. Weksler BB, Kent JL, Rudolph D, Scherer PB, Levy DE. Effects of low dose aspirin on platelet function in patients with recent cerebral ischemia. Stroke 1985;16:5-9
28. Berglund U, Wallentin L. Persistent inhibition of platelet function during long-term treatment with 75 mg acetylsalicylic acid daily in men with unstable coronary artery disease. Eur Heart J 1991;12:428-433
29. Kundu SK, Heilmann EJ, Sio R, Garcia C, Ostgaard RA. Description of an in vitro platelet function analyzer, PFA-100. Semin Thromb Hemost 1995;21:106-112
30. Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital and acquired platelet dysfunction. J Lab Clin Med 2001;138:152-163
31. Mammen EF, Comp PC, Gosselin R, et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24:195-202
32. Fressinaud E, Veyradier A, Truchoud I, et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood 1998;91:1325-1331
33. Böck M, de Haan J, Beck KH, et al. Standardization of the PFA-100 platelet function test in 105 mmol/L buffered citrate: effect of gender, smoking, and oral contraceptives. Br J Haematol 1999;106:898-904
34. Macchi L, Christiaens L, Brabant S, et al. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res 2002;107:45-49
35. ten Berg JM, Gerritsen WBM, Haas FJLM, Kelder HC, Verheugt FW, Plokker HW. High-dose aspirin in addition to daily low-dose aspirin decreases platelet activation in patients before and after percutaneous coronary intervention. Thromb Res 2002;105:385-390
36. Hézard N, Metz D, Nazeyrollas P, Droulle C, Potron G, Nguyen P. PFA-100 and flow cytometry: can they challenge aggregometry to assess antiplatelet agents, other than GPIIbIIIa blockers, in coronary angioplasty? Thromb Res 2002;108:43-47
37. Harrison P. Progress in the assessment of platelet function. Br J Haematol 2000;111:733-744
38. Homoncik M, Jilma B, Hergovich N, Stohlawetz P, Panzer S, Speiser W. Monitoring of aspirin (ASA) pharmacodynamics with the platelet function analyzer PFA-100. Thromb Haemost 2000;83:316-321
39. Grundmann K, Jaschonek K, Kleine B, Dichgans J, Topka H. Aspirin non-responder status in patients with recurrent cerebral ischemic attacks. J Neurol 2003;250:63-66
40. Grotemeyer KH. Effects of acetylsalicylic acid in stroke patients-evidence of nonresponders in a subpopulation of treated patients. Thromb Res 1991;63:587-593
41. FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983;67:1174-1177
42. Granström E. Methodology in prostaglandin and thromboxane assay. Prog Lipid Res 1986;25:119-127